CDMRP PRMRP Clinical Trial Award for Emerging Viral Diseases and Respiratory Health | W81XWH 20 PRMRP CTA COV

Opportunity Information: Apply for W81XWH 20 PRMRP CTA COV

The CDMRP PRMRP Clinical Trial Award for Emerging Viral Diseases and Respiratory Health is a Department of Defense (DoD) funding opportunity intended to move quickly on human clinical research that can make a meaningful difference in priority areas tied to Emerging Viral Diseases and Respiratory Health. Run through the U.S. Army Medical Research Acquisition Activity (USAMRAA) under the Congressionally Directed Medical Research Programs (CDMRP), the award is built for studies that are ready to be tested in people and that have a clear path to impact within one or more Focus Areas listed in the funding announcement for FY20. The central aim is speed and relevance: getting well-justified clinical trials underway without spending the award on earlier-stage animal or purely preclinical work.

This mechanism specifically supports clinical trials that prospectively assign one or more human subjects to one or more interventions in order to measure biomedical or behavioral health outcomes. In practice, that means the project must involve an intervention (or interaction) delivered to participants, potentially including a placebo or other control, and then the study team evaluates how that intervention affects outcomes in the participants. The announcement emphasizes that the outcomes should represent direct effects of the intervention on the subjects. The term "human subjects" is used to describe the individuals who will be recruited for or enrolled in the proposed trial, and applicants are directed to consult the Human Subject Resource Document available through eBRAP for additional guidance and expectations.

The types of interventions and trial concepts the program is willing to support are broad, as long as they align with the focus areas and are appropriate for a clinical trial framework. Examples explicitly called out include promising new products, pharmacologic agents such as drugs or biologics, devices, clinical guidance, and emerging approaches or technologies. The program is also flexible on trial stage and scale. It can support smaller, early proof-of-concept efforts such as pilot studies, first-in-human studies, or Phase 0 work meant to demonstrate feasibility or generate the information needed to design a more definitive study. At the other end of the spectrum, it can also support larger trials designed to determine efficacy in relevant patient populations, provided the project is positioned to execute and deliver interpretable results.

A key constraint is that the award funds must be used to support a clinical trial and cannot be used for animal studies. Applicants who are still at the preclinical stage are advised to look to other FY20 PRMRP program announcements rather than this clinical trial-specific mechanism. In other words, the program is not meant to bridge from bench to bedside in the same award; it is meant to pay for the bedside trial itself.

Administratively, the opportunity is listed as discretionary funding and may be offered as either a grant or a cooperative agreement, under the Science and Technology and other Research and Development category (CFDA 12.420). Eligibility is described as unrestricted, meaning it is broadly open to applicant organizations, subject to any additional eligibility clarifications contained in the full announcement. The opportunity number is W81XWH-20-PRMRP-CTA-COV, with an original closing date of June 22, 2020, and an estimated five awards. The notice lists an award ceiling of 0, which typically indicates that the maximum amount is not specified in the summary field and that applicants should rely on the full funding announcement for budget limits, expectations, and any caps that may apply.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "CDMRP PRMRP Clinical Trial Award for Emerging Viral Diseases and Respiratory Health" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 08, 2020.
• Applicants must submit their applications by Jun 22, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 20 PRMRP CTA COV

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: